Carlos M. R.
- Country
- Spain
- Department
- Servicio de Neumología
Research Overview
- Long-term safety and efficacy of subcutaneous lunsekimig in adults with asthma: An open-label extension study
- Phase 2b/3 Randomized Double‑Blind Placebo‑Controlled Study Evaluating Efficacy and Safety of Lunsekimig in Adults with Inadequately Controlled Eosinophilic COPD
- Phase 3b/4 Randomized Double‑Blind Study of Depemokimab 100 mg SC Q26 weeks vs Placebo on Exacerbations and Lung‑Function Decline in Adults/Adolescents with Type 2 Asthma
Data & Insights
Has run more than one trial at 141 of 349 partner sites.
Specializations
Respiratory Disease Management
This investigator specializes in treating various forms of severe asthma, with particular expertise in eosinophilic asthma and its advanced therapeutic approaches. Their work involves evaluating novel treatment options for patients whose conditions remain uncontrolled on standard therapies.
- Eosinophilic Phenotype Assessment
- Severe Asthma Control Strategies
- Maintenance Therapy Optimization
Chronic Cough Treatment
The investigator focuses on developing therapeutic solutions for patients with refractory chronic cough and unexplained chronic cough. Their expertise extends to long-term management strategies and innovative treatment approaches for persistent cough conditions.
- Cough Frequency Assessment
- Novel Therapeutic Evaluation
- Long-term Safety Monitoring
Biological Therapy Innovation
The investigator evaluates advanced biological treatments for respiratory conditions, including assessment of novel agents like benralizumab, tezepelumab, and depemokimab. Their work focuses on comparing treatment efficacies and exploring medication reduction strategies in controlled patients.
- Targeted Biological Therapies
- Treatment Response Assessment
- Medication Reduction Protocols
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.